A detailed history of Transcendent Capital Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Transcendent Capital Group LLC holds 224 shares of VRTX stock, worth $105,907. This represents 0.05% of its overall portfolio holdings.

Number of Shares
224
Previous 740 69.73%
Holding current value
$105,907
Previous $347 Million 69.96%
% of portfolio
0.05%
Previous 0.2%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$460.0 - $505.78 $237,360 - $260,982
-516 Reduced 69.73%
224 $104 Million
Q2 2024

Jul 24, 2024

BUY
$392.81 - $485.53 $202,689 - $250,533
516 Added 230.36%
740 $347 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $41,584 - $45,500
-102 Reduced 31.29%
224 $93.6 Million
Q4 2023

Mar 01, 2024

BUY
$343.0 - $410.68 $111,818 - $133,881
326 New
326 $133 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Transcendent Capital Group LLC Portfolio

Follow Transcendent Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Transcendent Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Transcendent Capital Group LLC with notifications on news.